Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Chfr inactivation is not associated to chromosomal instability in colon cancers

Oncogene volume 22, pages 8956–8960 (2003)Cite this article

Abstract

Numerous observations suggest that chromosome instability is caused by mitotic abnormalities such as errors in the partitioning of chromosomes. Chfr was recently defined as a central component of a new mitotic checkpoint that delays chromosome condensation in response to mitotic stress. Chfr was shown to be frequently inactivated in several human neoplasms, including colon, lung and esophageal cancers. To test whether Chfr inactivation may lead or participate to chromosomal instability (CIN), we analysed the genetic and epigenetic status of the gene in a large panel of primary colon and breast cancers, as well as in colon and breast cancer cell lines displaying either a microsatellite instability or a CIN. Our results confirm that Chfr is frequently inactivated in colon cancers, through a mechanism of hypermethylation of the promoter sequences. In contrast, the loss of Chfr expression appears to be a rare event in breast cancers. Furthermore, our data demonstrate that Chfr inactivation is not associated with CIN in these frequent types of human cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Ahuja N, Mohan AL, Li Q, Stolker JM, Herman JG, Hamilton SR, Baylin SB and Issa JP . (1997). Cancer Res., 57, 3370–3374.

  • Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW, Vogelstein B and Lengauer C . (2002). Cancer Res., 62, 1129–1133.

  • Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW and Vogelstein B . (1998). Nature, 392, 300–303.

  • Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD and El-Deiry WS . (2003). Carcinogenesis, 24, 47–51.

  • Doxsey S . (2002). Mol. Cell, 10, 439–440.

  • Duval A and Hamelin R . (2002). Ann. Genet., 45, 71–75.

  • Forozan F, Mahlamaki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A and Kallioniemi OP . (2000). Cancer Res., 60, 4519–4525.

  • Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P and Hamelin R . (2001). Oncogene, 20, 5025–5032.

  • Ghadimi BM, Sackett DL, Difilippantonio MJ, Schrock E, Neumann T, Jauho A, Auer G and Ried T . (2000). Genes Chromosomes Cancer, 27, 183–190.

  • Gioanni J, Le Francois D, Zanghellini E, Mazeau C, Ettore F, Lambert JC, Schneider M and Dutrillaux B . (1990). Br. J. Cancer, 62, 8–13.

  • Imai Y, Shiratori Y, Kato N, Inoue T and Omata M . (1999). Jpn. J. Cancer Res., 90, 837–840.

  • Jackson AL and Loeb LA . (1998). Semin. Cancer Biol., 8, 421–429.

  • Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW and Waldman FM . (1994). Proc. Natl. Acad. Sci. USA, 91, 2156–2160.

  • Kang D, Chen J, Wong J and Fang G . (2002). J. Cell Biol., 156, 249–259.

  • Kytola S, Rummukainen J, Nordgren A, Karhu R, Farnebo F, Isola J and Larsson C . (2000). Genes Chromosomes Cancer, 28, 308–317.

  • Lengauer C, Kinzler KW and Vogelstein B . (1998). Nature, 396, 643–649.

  • Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C and Salisbury JL . (2002). Proc. Natl. Acad. Sci. USA, 99, 1978–1983.

  • Loeb LA and Christians FC . (1996). Mutat. Res., 350, 279–286.

  • Luker KE, Pica CM, Schreiber RD and Piwnica-Worms D . (2001). Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res., 61, 6540–6547.

    CAS  PubMed  Google Scholar 

  • Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y and Takahashi T . (2002). Oncogene, 21, 2328–2333.

  • Paulovich AG, Toczyski DP and Hartwell LH . (1997). Cell, 88, 315–321.

  • Rummukainen J, Kytola S, Karhu R, Farnebo F, Larsson C and Isola JJ . (2001). Cancer Genet. Cytogenet., 126, 1–7.

  • Sato M, Sekido Y, Horio Y, Takahashi M, Saito H, Minna JD, Shimokata K and Hasegawa Y . (2000). Jpn. J. Cancer Res., 91, 504–509.

  • Scolnick DM and Halazonetis TD . (2000). Nature, 406, 430–435.

  • Sen S . (2000). Curr. Opin. Oncol., 12, 82–88.

  • Sen S, Zhou H and White RA . (1997). Oncogene, 14, 2195–2200.

  • Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, Kudo J, Terashita Y, Konishi S, Sugiura H and Fujii Y . (2002). Carcinogenesis, 23, 1695–1699.

  • Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP . (1999). Proc. Natl. Acad. Sci. USA, 96, 8681–8686.

  • Tsushimi T, Noshima S, Oga A, Esato K and Sasaki K . (2001). Cancer Genet. Cytogenet., 126, 34–38.

  • Wang Q, Moyret-Lalle C, Couzon F, Surbiguet-Clippe C, Saurin JC, Lorca T, Navarro C and Puisieux A . (2003). Oncogene, 22, 1486–1490.

  • Wheeler JM, Beck NE, Kim HC, Tomlinson IP, Mortensen NJ and Bodmer WF . (1999). Proc. Natl. Acad. Sci. USA, 96, 10296–10301.

  • Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S . (1998). Nat. Genet., 20, 189–193.

Download references

Acknowledgements

We thank T Halazonetis for Chfr constructs. This work was supported by grants from the Comité Départemental du Rhône and the Comité Départemental de l'Ain de la Ligue de Lutte contre le Cancer, and from the Association pour la Recherche sur le Cancer.

Author information

Authors and Affiliations

  1. Unité d'Oncologie Moléculaire, INSERM U590, Centre Léon Bérard, 28 rue Laënnec, Lyon, Cedex 08, 69373, France

    Jacques Bertholon, Qing Wang, Nicole Falette, Carole Verny, Jessie Auclair, Christelle Chassot, Claudine Navarro & Alain Puisieux

  2. Faculté de Pharmacie, 8 avenue Rockefeller, Lyon, Cedex 08, 69373, France

    Jacques Bertholon & Alain Puisieux

  3. Fédération de Spécialités Digestives, Hôpital Edouard Herriot, Place d'Arsonval, Lyon, Cedex 03, 69437, France

    Jean-Christophe Saurin

Authors
  1. Jacques Bertholon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicole Falette
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carole Verny
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jessie Auclair
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christelle Chassot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Claudine Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean-Christophe Saurin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alain Puisieux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alain Puisieux.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertholon, J., Wang, Q., Falette, N. et al. Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene 22, 8956–8960 (2003). https://doi.org/10.1038/sj.onc.1207078

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207078

Keywords

This article is cited by

Search

Advanced search

Quick links